BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 27, 2005
View Archived Issues
Experimental Study Supports Population Selection In Viruses
Read More
Alexza Files For $86.25M IPO To Carry Aerosol Drug Work
Read More
Holiday notice
Read More
Appointments And Advancements
Read More
Other News To Note
Read More
Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M
Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today)
Read More
EntreMed Acquiring Cancer Company Miikana For $21M
Read More
